Namenda

This page shows the latest Namenda news and features for those working in and with pharma, biotech and healthcare.

Forest said to be interested in $3bn Aptalis acquisition

US for former blockbuster antidepressant Lexapro (escitalopram), as well as generic competition from 2015 for Alzheimer's disease therapy Namenda (memantine). ... With Lexapro and Namenda accounting for more than three quarters of company turnover at

Latest news

Lundbeck and Otsuka take Alzheimer's drug into phase III

Regardless, it has been 10 years since the last new Alzheimer's treatment reached the market - Lundbeck's glutamate (NMDA) antagonist Ebixa (memantine), which is sold as Namenda by Forest Labs
Lexapro generics hammer Forest Labs' Q3 results

On the plus side, Alzheimer's drug Namenda (memantine) achieved a 9 per cent hike in sales to $368m, while antihypertensive Bystolic (nebivolol) was up almost 30 per cent to $106m. ... With Lexapro now completely genericised we have a bright future with
Forest's net income down for Q3

He said: "We have been working diligently for the past seven years to build a solid product development pipeline that will more than replace the loss of Lexapro and Namenda following
Forest Laboratories earnings rise

Lexapro (escitalopram) and its Alzheimer's drug Namenda (memantine) lose their patent protection in the coming years. ... expiration for both Lexapro in 2012 and Namenda in 2015 and provide growth," he said.
Lifting the fog

Additionally, a patch formulation of donepezil is in development. Also approved for the treatment of moderate-to-severe AD is memantine (Namenda, Forest Laboratories), which was the first NMDA receptor antagonist

More from news
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Pharma deals during January 2014

Not disclosed. Adamas. Forest. Completion of studies for the NDA of a fixed dosed combination of Namenda and donepezil, Forest has exclusive US commercialisation rights.
Pharma deals during November 2012

Development / commercialisation. Fixed dose combination of Namenda and donepezil for AD.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Medical Writers Required - Hertfordshire: Competitive

Healthcare PR Senior Account Manager: Salary TBC

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Systematic Review Lead- London: Negotiable

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Manager: Negotiable

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Account Manager – Healthcare Advertising: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Medical Writer - Creative and Scientific Projects: DOE

Associate Scientific Director: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Medical Writer, MedComms Agency: Salary TBC

Graduate Scientific Editor: DOE

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Writer, Healthcare Advertising, London: Excellent package

Account Director, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer: Salary is DOE

Subscribe to our email news alerts

PMHub

Add my company

BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....